S1P1受体激动剂SEW2871在脓毒症中引起严重心脏副作用且不改善微血管屏障破坏
本研究在盲肠升支支架腹膜炎(CASP)脓毒症大鼠模型中评估S1P1受体激动剂SEW2871对内皮屏障功能的影响。术后12小时给予SEW2871或氯化钠,24小时后用活体显微镜评估肠系膜内皮屏障功能。体外实验中SEW2871部分稳定了TNF-α诱导的内皮屏障破坏,但体内SEW2871引起脓毒症动物严重心脏副作用并增加死亡率,未减轻内皮屏障功能障碍(FITC-白蛋白外渗增加、需要血管内液体补充、肺水肿)。假手术动物接受SEW2871后未出现副作用。作者认为给药时机和促炎环境对SEW2871的治疗获益起关键作用。
要点
- 在CASP脓毒症大鼠中,SEW2871引起严重心脏副作用并增加死亡率,未改善脓毒症诱导的内皮屏障功能障碍。
- SEW2871未能减少肠系膜FITC-白蛋白外渗、未能降低血管内液体补充需求、未减轻肺水肿。
- 体外实验中SEW2871部分稳定了TNF-α诱导的内皮屏障破坏,但体内无效且有害。
- 假手术动物接受SEW2871后未出现任何副作用,提示脓毒症促炎环境放大了心脏毒性。
- 作者认为给药时机和促炎环境对SEW2871的治疗获益起关键作用。
适用人群与场景
- Sprague-Dawley大鼠,采用CASP模型诱导多微生物脓毒症,术后12小时给药。
- 体外实验使用人真皮微血管内皮细胞。
- 假手术动物接受SEW2871后未出现副作用。
处置流程与药物剂量
- 术后12小时,脓毒症大鼠接受SEW2871或氯化钠(原文未写明剂量、途径和频次)。
- 24小时后通过活体显微镜评估肠系膜内皮屏障功能。
红旗征与不能漏的情况
- SEW2871在脓毒症动物中引起严重心脏副作用,导致死亡率增加。
研究设计与关键结果
- 研究类型:动物实验(CASP脓毒症大鼠模型)及体外细胞实验。
- 体外:SEW2871部分稳定了TNF-α诱导的内皮屏障破坏。
- 体内:SEW2871引起脓毒症动物严重心脏副作用,死亡率增加;未减轻内皮屏障功能障碍,表现为FITC-白蛋白外渗增加、需要血管内液体补充、肺水肿。
- 假手术动物接受SEW2871后未出现副作用。
证据类型、等级与局限
- 证据类型:动物实验和体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,给药时机和促炎环境对SEW2871的治疗获益起关键作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Endothelial barrier dysfunction is a hallmark in the pathogenesis of sepsis. Sphingosine-1-phosphate (S1P) has been proposed to be critically involved in the maintenance of endothelial barrier function predominately by activating S1P receptor-1 (S1P1). Previous studies have shown that the specific S1P1 agonist SEW2871 improves endothelial barrier function under inflammatory conditions. However, the effectiveness of SEW2871 and potential side effects remained largely unexplored in a clinically relevant model of sepsis. Therefore, this study aimed to evaluate the effects of SEW2871 in the Colon ascendens stent peritonitis (CASP) model.
METHODS: Polymicrobial sepsis was induced in Sprague-Dawley rats using CASP model that enabled the monitoring of macro-hemodynamic parameters. Twelve hours after surgery, animals received either SEW2871 or sodium chloride. Mesenteric endothelial barrier function was evaluated 24 h after sepsis induction by intravital microscopy. Organ pathology was assessed in lungs. S1P levels, blood gas analyses, and blood values were measured at different time points. In parallel the effect of SEW2871 was evaluated in human dermal microvascular endothelial cells.
RESULT: In vitro SEW2871 partially stabilized TNF-α-induced endothelial barrier breakdown. However, in vivo SEW2871 caused severe cardiac side effects in septic animals leading to an increased lethality. Sepsis-induced endothelial barrier dysfunction was not attenuated by SEW2871 as revealed by increased FITC-albumin extra-vasation, requirement of intravasal fluid replacement, and pulmonary edema. Interestingly, Sham-operated animals did not present any side effects after SEW2871 treatment.
CONCLUSION: Our study demonstrates that the application of SEW2871 causes severe cardiac side effects and cannot attenuate the inflammation-induced endothelial barrier breakdown in a clinically relevant sepsis model, suggesting that the time point of administration and the pro-inflammatory milieu play a pivotal role in the therapeutic benefit of SEW2871.
参考来源
- Flemming S, Burkard N, Meir M, et al. Sphingosine-1-Phosphate Receptor-1 Agonist Sew2871 Causes Severe Cardiac Side Effects and Does Not Improve Microvascular Barrier Breakdown in Sepsis. Shock. 2018. PMID: 28538086. doi:10.1097/SHK.0000000000000908
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。